Privigen 100mg/ml solution for infusion
Replacement therapy in adults, and children and adolescents (0-18 years) in: • Primary immunodeficiency syndromes (PID) with impaired antibody production (see section 4.4). • Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum level of <4 g/l. * PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines. Immunomodulation in adults, and children and adolescents (0-18 years) in: • Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count. • Guillain-Barré syndrome. • Kawasaki disease. • Chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP. • Multifocal motor neuropathy (MMN).